Table 4

Pondered bacterial resistance to the antimicrobials recommended for empirical treatment of urinary tract infection
Resistance to first-line therapy Resistance to second-line therapy
Bacteria Incidence (%) PIV (%) PIV (%)1 NIT (%) NIT (%)1 AMX-CLA (%) AMX-CLA (%)1 SXT (%) SXT (%)1 FLU (%) FLU (%)1
E. coli 64.5 15.8 10.2 6.0 3.9 7.5 4.8 25.4 16.4 14.1 9.1
S. aureus 6.0 8.3 0.5 15.6 0.9 18.8 1.2
P. mirabilis 4.7 37.7 1.8 95.1 4.5 11.8 0.6 41.5 2.0 22.2 1.1
Klebsiella spp 4.3 24.8 1.1 32.8 1.4 81.6 3.5 36.0 1.5 22.3 1.0
E. faecalis 3.6 8.0 0.3 9.5 0.3 35.5 1.3 41.1 1.5
P. vulgaris 2.7 59.1 1.6 97.1 2.6 32.9 0.9 57.3 1.5 25.3 0.7
P. aeruginosa 2.4 44.3 1.1
Enterobacter spp 1.9 46.7 0.9 39.5 0.8 83.2 1.6 39.3 0.7 25.7 0.5
Snn epidermidis 1.8 3.0 0.1 25.9 0.5 26.1 0.5
Providencia 1.7 24.2 0.4 87.3 1.5 18.4 0.3 23.1 0.4 18.9 0.3
Pondered Resistance (%) 15.9 14.9 12.6 25.2 16.8

The pondered bacterial resistance was determined having into account the incidence and resistance of each bacterium. For the fluoroquinolones the pondered bacterial resistance by sex was also determined (25.6% for males and 14.3% for females).

Linhares et al.

Linhares et al. BMC Infectious Diseases 2013 13:19   doi:10.1186/1471-2334-13-19

Open Data